Trial Profile
A Randomized, Phase 1b/2 Trial of Rilotumumab or Ganitumab in Combination With Panitumumab Versus Panitumumab Alone in Subjects With Wild-Type KRAS Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Ganitumab (Primary) ; Rilotumumab (Primary) ; Panitumumab
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 22 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 28 Apr 2012 Planned number of patients changed from 132 to 153 as reported by European Clinical Trials Database.